Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04626921 (ClinicalTrials.gov)	October 22, 2020	30/10/2020	A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis	VISIONARY-MS LTE: A Multi-Center, Open-Label Long-Term Extension Study Assessing the Safety, Efficacy, Tolerability, and Pharmacokinetics of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: CNM-Au8	Clene Nanomedicine	George Clinical	Active, not recruiting	18 Years	55 Years	All	150	Phase 2/Phase 3	Australia;Canada;United States
2	NCT03993171 (ClinicalTrials.gov)	December 19, 2019	31/5/2019	31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.	A Phase 2, Open-Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis.	Relapsing Remitting Multiple Sclerosis	Drug: gold nanocrystals	Clene Nanomedicine	University of Texas Southwestern Medical Center	Recruiting	18 Years	55 Years	All	30	Phase 2	United States